This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd HC, Hayhurst KP, Murray RM, Markwick A, Lewis SW.Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63: 1079-1087, No. 10, Oct 2006
Lieberman JA.Comparative effectiveness of antipsychotic drugs: a commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Archives of General Psychiatry 63: 1069-1072, No. 10, Oct 2006
Rosenheck RA.Outcomes, costs, and policy caution: a commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63: 1074-1076, No. 10, Oct 2006
Rights and permissions
About this article
Cite this article
First-generation antipsychotics get second wind in schizophrenia. Pharmacoecon. Outcomes News 518, 8 (2006). https://doi.org/10.2165/00151234-200605180-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605180-00025